Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Parathyroid Disorders Market

ID: MRFR/Pharma/18456-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026

US Parathyroid Disorders Market Research Report By Type of Disorder (Primary Hyperparathyroidism, Secondary Hyperparathyroidism, Tertiary Hyperparathyroidism), By Treatment Type (Medications, Surgery, Radiation Therapy, Observation), By Diagnosis Method (Blood Tests, Imaging Tests, Biopsies) and By Patient Age Group (Children, Adults, Elderly) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Parathyroid Disorders Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Life Sciences, BY Type of Disorder (USD Million)
      1. 4.1.1 Primary Hyperparathyroidism
      2. 4.1.2 Secondary Hyperparathyroidism
      3. 4.1.3 Tertiary Hyperparathyroidism
    2. 4.2 Life Sciences, BY Treatment Type (USD Million)
      1. 4.2.1 Medications
      2. 4.2.2 Surgery
      3. 4.2.3 Radiation Therapy
      4. 4.2.4 Observation
    3. 4.3 Life Sciences, BY Diagnosis Method (USD Million)
      1. 4.3.1 Blood Tests
      2. 4.3.2 Imaging Tests
      3. 4.3.3 Biopsies
    4. 4.4 Life Sciences, BY Patient Age Group (USD Million)
      1. 4.4.1 Children
      2. 4.4.2 Adults
      3. 4.4.3 Elderly
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Life Sciences
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Amgen Inc (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb Company (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Eli Lilly and Company (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis AG (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Pfizer Inc (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Sanofi S.A. (FR)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Teva Pharmaceutical Industries Ltd (IL)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 AbbVie Inc (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE OF DISORDER
    3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
    4. 6.4 US MARKET ANALYSIS BY DIAGNOSIS METHOD
    5. 6.5 US MARKET ANALYSIS BY PATIENT AGE GROUP
    6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
    9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
    11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
    12. 6.12 LIFE SCIENCES, BY TYPE OF DISORDER, 2024 (% SHARE)
    13. 6.13 LIFE SCIENCES, BY TYPE OF DISORDER, 2024 TO 2035 (USD Million)
    14. 6.14 LIFE SCIENCES, BY TREATMENT TYPE, 2024 (% SHARE)
    15. 6.15 LIFE SCIENCES, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 LIFE SCIENCES, BY DIAGNOSIS METHOD, 2024 (% SHARE)
    17. 6.17 LIFE SCIENCES, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
    18. 6.18 LIFE SCIENCES, BY PATIENT AGE GROUP, 2024 (% SHARE)
    19. 6.19 LIFE SCIENCES, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE OF DISORDER, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
      4. 7.2.4 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Life Sciences Market Segmentation

Life Sciences By Type of Disorder (USD Million, 2025-2035)

  • Primary Hyperparathyroidism
  • Secondary Hyperparathyroidism
  • Tertiary Hyperparathyroidism

Life Sciences By Treatment Type (USD Million, 2025-2035)

  • Medications
  • Surgery
  • Radiation Therapy
  • Observation

Life Sciences By Diagnosis Method (USD Million, 2025-2035)

  • Blood Tests
  • Imaging Tests
  • Biopsies

Life Sciences By Patient Age Group (USD Million, 2025-2035)

  • Children
  • Adults
  • Elderly

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions